Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
44
MRVI Quote, Financials, Valuation and Earnings
Last price:
$3.43
Seasonality move
:
-3.88%
Day range:
$3.40 - $3.56
52-week range:
$1.67 - $6.21
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.56x
P/B ratio:
2.03x
Volume:
1.2M
Avg. volume:
1.4M
1-year change:
-36.83%
Market cap:
$497.4M
Revenue:
$259.2M
EPS (TTM):
-$0.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MRVI
Maravai Lifesciences Holdings, Inc.
|
$50.6M | -$0.05 | -13.08% | -61.95% | $3.93 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $2.09 | 98.47% | -58.59% | $491.92 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$58.9M | -$1.08 | 8945.75% | -93.1% | $64.08 |
|
INSM
Insmed, Inc.
|
$191.7M | -$1.18 | 63.57% | -7.7% | $214.78 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$82.8M | -$0.15 | 11.5% | -35.2% | $8.35 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$306.1M | -$0.73 | 201.09% | -93.09% | $603.47 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MRVI
Maravai Lifesciences Holdings, Inc.
|
$3.43 | $3.93 | $497.4M | -- | $0.00 | 0% | 2.56x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$400.23 | $491.92 | $52.9B | 1,664.16x | $0.00 | 0% | 16.42x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$68.16 | $64.08 | $9.3B | -- | $0.00 | 0% | 10.97x |
|
INSM
Insmed, Inc.
|
$174.84 | $214.78 | $37.3B | -- | $0.00 | 0% | 74.41x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.48 | $8.35 | $984.5M | -- | $0.00 | 0% | 3.28x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$591.02 | $603.47 | $13.4B | -- | $0.00 | 0% | 17.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MRVI
Maravai Lifesciences Holdings, Inc.
|
59.99% | 3.612 | 61.14% | 4.32x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
61.15% | 4.654 | 15.55% | 4.74x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.206 | 6.28% | 2.92x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
35.63% | -0.048 | 3.33% | 3.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MRVI
Maravai Lifesciences Holdings, Inc.
|
$5.1M | -$8.8M | -23.17% | -40.88% | -21.15% | -$18.1M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$250.1M | $44.1M | 2.57% | 7.7% | 17.2% | $13M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$268.8M | -$114M | -32.91% | -40.56% | -39.68% | $76M |
Maravai Lifesciences Holdings, Inc. vs. Competitors
-
Which has Higher Returns MRVI or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -108.23% compared to Maravai Lifesciences Holdings, Inc.'s net margin of 20.1%. Maravai Lifesciences Holdings, Inc.'s return on equity of -40.88% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital MRVIMaravai Lifesciences Holdings, Inc.12.14% -$0.18 $799.8M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About MRVI or ALNY?
Maravai Lifesciences Holdings, Inc. has a consensus price target of $3.93, signalling upside risk potential of 14.54%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 22.91%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Maravai Lifesciences Holdings, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Maravai Lifesciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRVIMaravai Lifesciences Holdings, Inc.5 6 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is MRVI or ALNY More Risky?
Maravai Lifesciences Holdings, Inc. has a beta of 0.326, which suggesting that the stock is 67.413% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock MRVI or ALNY?
Maravai Lifesciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maravai Lifesciences Holdings, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRVI or ALNY?
Maravai Lifesciences Holdings, Inc. quarterly revenues are $41.6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Maravai Lifesciences Holdings, Inc.'s net income of -$45.1M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Maravai Lifesciences Holdings, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,664.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maravai Lifesciences Holdings, Inc. is 2.56x versus 16.42x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRVIMaravai Lifesciences Holdings, Inc.2.56x -- $41.6M -$45.1M ALNYAlnylam Pharmaceuticals, Inc.16.42x 1,664.16x $1.2B $251.1M
-
Which has Higher Returns MRVI or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -108.23% compared to Maravai Lifesciences Holdings, Inc.'s net margin of 6.29%. Maravai Lifesciences Holdings, Inc.'s return on equity of -40.88% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7%.
Company Gross Margin Earnings Per Share Invested Capital MRVIMaravai Lifesciences Holdings, Inc.12.14% -$0.18 $799.8M ARWRArrowhead Pharmaceuticals, Inc.97.51% -$0.18 $1.2B -
What do Analysts Say About MRVI or ARWR?
Maravai Lifesciences Holdings, Inc. has a consensus price target of $3.93, signalling upside risk potential of 14.54%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $64.08 which suggests that it could fall by -5.98%. Given that Maravai Lifesciences Holdings, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Maravai Lifesciences Holdings, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRVIMaravai Lifesciences Holdings, Inc.5 6 0 ARWRArrowhead Pharmaceuticals, Inc.7 4 0 -
Is MRVI or ARWR More Risky?
Maravai Lifesciences Holdings, Inc. has a beta of 0.326, which suggesting that the stock is 67.413% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, suggesting its more volatile than the S&P 500 by 27.862%.
-
Which is a Better Dividend Stock MRVI or ARWR?
Maravai Lifesciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maravai Lifesciences Holdings, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRVI or ARWR?
Maravai Lifesciences Holdings, Inc. quarterly revenues are $41.6M, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $256.5M. Maravai Lifesciences Holdings, Inc.'s net income of -$45.1M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M. Notably, Maravai Lifesciences Holdings, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maravai Lifesciences Holdings, Inc. is 2.56x versus 10.97x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRVIMaravai Lifesciences Holdings, Inc.2.56x -- $41.6M -$45.1M ARWRArrowhead Pharmaceuticals, Inc.10.97x -- $256.5M $16.1M
-
Which has Higher Returns MRVI or INSM?
Insmed, Inc. has a net margin of -108.23% compared to Maravai Lifesciences Holdings, Inc.'s net margin of -259.95%. Maravai Lifesciences Holdings, Inc.'s return on equity of -40.88% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital MRVIMaravai Lifesciences Holdings, Inc.12.14% -$0.18 $799.8M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About MRVI or INSM?
Maravai Lifesciences Holdings, Inc. has a consensus price target of $3.93, signalling upside risk potential of 14.54%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 22.84%. Given that Insmed, Inc. has higher upside potential than Maravai Lifesciences Holdings, Inc., analysts believe Insmed, Inc. is more attractive than Maravai Lifesciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRVIMaravai Lifesciences Holdings, Inc.5 6 0 INSMInsmed, Inc.17 1 0 -
Is MRVI or INSM More Risky?
Maravai Lifesciences Holdings, Inc. has a beta of 0.326, which suggesting that the stock is 67.413% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock MRVI or INSM?
Maravai Lifesciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maravai Lifesciences Holdings, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRVI or INSM?
Maravai Lifesciences Holdings, Inc. quarterly revenues are $41.6M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Maravai Lifesciences Holdings, Inc.'s net income of -$45.1M is higher than Insmed, Inc.'s net income of -$370M. Notably, Maravai Lifesciences Holdings, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maravai Lifesciences Holdings, Inc. is 2.56x versus 74.41x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRVIMaravai Lifesciences Holdings, Inc.2.56x -- $41.6M -$45.1M INSMInsmed, Inc.74.41x -- $142.3M -$370M
-
Which has Higher Returns MRVI or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -108.23% compared to Maravai Lifesciences Holdings, Inc.'s net margin of -135.28%. Maravai Lifesciences Holdings, Inc.'s return on equity of -40.88% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital MRVIMaravai Lifesciences Holdings, Inc.12.14% -$0.18 $799.8M IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About MRVI or IOVA?
Maravai Lifesciences Holdings, Inc. has a consensus price target of $3.93, signalling upside risk potential of 14.54%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.35 which suggests that it could grow by 236.69%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Maravai Lifesciences Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Maravai Lifesciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRVIMaravai Lifesciences Holdings, Inc.5 6 0 IOVAIovance Biotherapeutics, Inc.6 4 1 -
Is MRVI or IOVA More Risky?
Maravai Lifesciences Holdings, Inc. has a beta of 0.326, which suggesting that the stock is 67.413% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.
-
Which is a Better Dividend Stock MRVI or IOVA?
Maravai Lifesciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maravai Lifesciences Holdings, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRVI or IOVA?
Maravai Lifesciences Holdings, Inc. quarterly revenues are $41.6M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Maravai Lifesciences Holdings, Inc.'s net income of -$45.1M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Maravai Lifesciences Holdings, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maravai Lifesciences Holdings, Inc. is 2.56x versus 3.28x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRVIMaravai Lifesciences Holdings, Inc.2.56x -- $41.6M -$45.1M IOVAIovance Biotherapeutics, Inc.3.28x -- $67.5M -$91.3M
-
Which has Higher Returns MRVI or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -108.23% compared to Maravai Lifesciences Holdings, Inc.'s net margin of -39.75%. Maravai Lifesciences Holdings, Inc.'s return on equity of -40.88% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.
Company Gross Margin Earnings Per Share Invested Capital MRVIMaravai Lifesciences Holdings, Inc.12.14% -$0.18 $799.8M MDGLMadrigal Pharmaceuticals, Inc.93.57% -$5.08 $972.1M -
What do Analysts Say About MRVI or MDGL?
Maravai Lifesciences Holdings, Inc. has a consensus price target of $3.93, signalling upside risk potential of 14.54%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 2.11%. Given that Maravai Lifesciences Holdings, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Maravai Lifesciences Holdings, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRVIMaravai Lifesciences Holdings, Inc.5 6 0 MDGLMadrigal Pharmaceuticals, Inc.13 1 0 -
Is MRVI or MDGL More Risky?
Maravai Lifesciences Holdings, Inc. has a beta of 0.326, which suggesting that the stock is 67.413% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.
-
Which is a Better Dividend Stock MRVI or MDGL?
Maravai Lifesciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maravai Lifesciences Holdings, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRVI or MDGL?
Maravai Lifesciences Holdings, Inc. quarterly revenues are $41.6M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Maravai Lifesciences Holdings, Inc.'s net income of -$45.1M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Maravai Lifesciences Holdings, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maravai Lifesciences Holdings, Inc. is 2.56x versus 17.70x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRVIMaravai Lifesciences Holdings, Inc.2.56x -- $41.6M -$45.1M MDGLMadrigal Pharmaceuticals, Inc.17.70x -- $287.3M -$114.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
